SP100 and primary biliary cholangitis: In particular, we investigated whether (a) the identification of PBC-specific autoantibodies against gp210 and sp100 would increase the diagnostic sensitivity of immunological testing for PBC, (b) the identification of AMA and PBC-specific anti-gp210 and anti-sp100 by immunodot and ELISA assays (based on molecularly defined antigens) would improve the sensitivity when compared to immunofluorescence-based techniques, and (c) the adoption of panels of autoantibodies would allow for the diagnosis of PBC in AMA negative patients, with the aim to minimize the risk of misclassification.